-Jonathan A Fletcher Researcher Activity Profile

Research Author Detailed Information 

Jonathan A Fletcher Publication Rate By Year

Jonathan A Fletcher has published 1 paper(s) in 1994, 1 paper(s) in 2004, 9 paper(s) in 2007, 4 paper(s) in 2008, for a total of 15 research publications in total.

Jonathan A Ja Fletcher Author Information

LAST NAME: fletcher

FIRST NAME: Jonathan A

INITIALS: ja

AFFILIATION:

Papers

Jonathan A Fletcher's Publication Record

1. Gastrointestinal stromal tumours: Etiology, pathology and clinical management. Year Published: 2004
Mount Sinai Hospital, Toronto, Canada.
2. Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors. Year Published: 2007
Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA.
3. Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors. Year Published: 2007
Department of Medicine, Children's Hospital Boston, MA, USA. katherine.janeway@childrens.harvard.edu
4. KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway. Year Published: 2007
Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02155, USA. sebastian.bauer@uni-due.de
5. Genetics of soft tissue tumors. Year Published: 2007
Department of Pathology, Stanford University Medical Center, Stanford, California 94305, USA. mrijn@stanford.edu
6. Genetics of soft tissue tumors. Year Published: 2007
Department of Pathology, Stanford University Medical Center, Stanford, California 94305, USA. mrijn@stanford.edu
7. Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors. Year Published: 2007
Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA.
8. Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors. Year Published: 2007
Department of Medicine, Children's Hospital Boston, MA, USA. katherine.janeway@childrens.harvard.edu
9. KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway. Year Published: 2007
Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02155, USA. sebastian.bauer@uni-due.de
10. Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors. Year Published: 2007
Department of Medicine, Children's Hospital Boston, MA, USA. katherine.janeway@childrens.harvard.edu
11. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. Year Published: 2008
Oregon Health and Science University Cancer Center and Portland Veterans Affairs Hospital, Portland, OR, USA. blankec@ohsu.edu
12. Percutaneous biopsy of peripheral primitive neuroectodermal tumors and Ewing's sarcomas for cytogenetic analysis. Year Published: 1994
Department of Radiology, Children's Hospital, Boston, MA 02115.
13. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. Year Published: 2008
Oregon Health and Science University Cancer Center and Portland Veterans Affairs Hospital, Portland, OR, USA. blankec@ohsu.edu
14. BRD-NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells. Year Published: 2008
1Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
15. BRD-NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells. Year Published: 2008
Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.